Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. 1998

S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
Department of Anesthesiology, University of Massachusetts Medical Center, Worcester 01655, USA.

OBJECTIVE To evaluate the efficacy of triple-lumen central venous catheters coated with a combination product of chlorhexidine and silver sulfadiazine (CSS) in reducing the incidence of local catheter infection and catheter-related bacteremia. METHODS Randomized, controlled trial. METHODS The surgical intensive care units in a university hospital. METHODS All patients who needed central venous catheterization were randomized to receive either an uncoated triple-lumen catheter (n = 157) or a catheter coated with CSS (n = 151). METHODS Catheters were removed when no longer needed or suspected as a cause of infection. The tip and a 5-cm segment of the intradermal portion of the catheter were cultured semiquantitatively. Blood cultures were obtained when clinically indicated. The remaining segment of catheters coated with CSS were cut and incubated on an agar plate with strains of Staphylococcus aureus and Enterococcus. Zone of inhibition was determined 24 hours later. Data were analyzed by survival and logistic multivariate regression methods. RESULTS Catheters coated with CSS were effective in reducing the rate of significant bacterial growth on either the tip or intradermal segment (40%) compared with control catheters (52%; P = .04). However, there was no difference in the incidence of catheter-related bacteremia (3.8% [uncoated] vs 3.3% [coated]; P = .81). In vitro activity of catheters with CSS against S aureus was evident up to 25 days but activity against Enterococcus dissipated more quickly over time and was absent by day 4. The most common colonizing organisms were coagulase-negative staphylococcus and enterococcus. Variables that were associated with a significant amount of growth on the tip or intradermal segment were a duration of catheterization of longer than 7 days, jugular insertion site, and the absence of a CSS coating. The use of a guidewire when the catheter was removed was associated with a lower risk of significant bacterial growth. CONCLUSIONS The use of CSS reduces the incidence of significant bacterial growth on either the tip or intradermal segments of coated triple-lumen catheters but has no effect on the incidence of catheter-related bacteremia. In this patient population, catheters coated with CSS provide no additional benefit over uncoated catheters.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002405 Catheterization, Central Venous Placement of an intravenous CATHETER in the subclavian, jugular, or other central vein. Central Venous Catheterization,Venous Catheterization, Central,Catheterization, Central,Central Catheterization,Catheterizations, Central,Catheterizations, Central Venous,Central Catheterizations,Central Venous Catheterizations,Venous Catheterizations, Central
D002710 Chlorhexidine A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque. Chlorhexidine Acetate,Chlorhexidine Hydrochloride,MK-412A,Novalsan,Sebidin A,Tubulicid,Acetate, Chlorhexidine,Hydrochloride, Chlorhexidine,MK 412A,MK412A
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000891 Anti-Infective Agents, Local Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. Anti-Infective Agents, Topical,Antiseptic,Antiseptics,Microbicides, Local,Microbicides, Topical,Antiinfective Agents, Local,Antiinfective Agents, Topical,Local Anti-Infective Agents,Local Antiinfective Agents,Topical Anti-Infective Agents,Topical Antiinfective Agents,Agents, Local Anti-Infective,Agents, Local Antiinfective,Agents, Topical Anti-Infective,Agents, Topical Antiinfective,Anti Infective Agents, Local,Anti Infective Agents, Topical,Local Anti Infective Agents,Local Microbicides,Topical Anti Infective Agents,Topical Microbicides
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012837 Silver Sulfadiazine Antibacterial used topically in burn therapy. Brandiazin,Dermazin,Flamazine,Flammazine,SSD,SSD AF,Sicazine,Silvadene,Silvederma,Sulfafdiazine, Silver,Sulfargen,Thermazene,Silver Sulfafdiazine,Sulfadiazine, Silver

Related Publications

S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
April 2004, Intensive care medicine,
S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
March 1996, Journal of clinical microbiology,
S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
October 1996, Journal of clinical microbiology,
S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
May 2004, Intensive care medicine,
S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
March 2014, American journal of infection control,
S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
October 2015, Journal of the American College of Surgeons,
S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
July 2009, The Journal of hospital infection,
S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
September 2009, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
May 1998, Masui. The Japanese journal of anesthesiology,
S O Heard, and M Wagle, and E Vijayakumar, and S McLean, and A Brueggemann, and L M Napolitano, and L P Edwards, and F M O'Connell, and J C Puyana, and G V Doern
December 2005, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
Copied contents to your clipboard!